Procedure: Innovative Drug MA (Novel NDA)
Country: Global Procedure
Version #: 12/07/2023
Author: Daria Kostiuchenko
Editor: Daria Kostiuchenko
ID: GP-PhR-NDA-SR
Category: Pharmaceuticals
Validity: Lifetime/5 years/country-specific
Certified by: Vlad Reznikov
Copyright: Pattern of USA Inc.
SUMMARY
The New Market Authorization (MA) for Innovative Drug Registration, known as Novel NDA, is a regulatory process facilitating the approval and introduction of new and innovative drugs to the market. This process involves a comprehensive assessment of the drug’s safety, efficacy, and quality by the NRA. The Novel NDA registration specifically targets drugs lacking prior approval or MA in a particular country.
The NDA is an extensive document providing data on animal and human studies, the drug’s pharmacology, toxicology, dosage, and details about the drug’s manufacturing process. It adopts the eCTD format as an interface and international specification for the pharmaceutical industry to transfer regulatory information to agencies. Additional specifications may be applicable at national and continental levels. In the U.S., the FDA supplements standard eCTD submissions with specifications such as PDF, transmission, file format, and supportive file requirements. Similarly, the EU EMA outlines the EU Module 1 specification and other quality assurance (QA) documents for eCTD submissions. It is important to note that Regional Module 1 varies by region and country, while Common Modules 2–5 remain consistent across countries.

Must-Have Requirements, Recognized Standards, and Certifications:
-
- cGMP/Establishment Registration
- NTE as NCE, NME, NAS, or NBE pertinence
- Rx or OTC drug designation
- Drug samples
- MAs in other countries & marketing history
- Pharmacologic class EPC/ATC definition
- Labeling and Medication Guide if applicable
- Compliance with eCTD incl. modules:
1. Administrative and prescribing information. 2. Common technical document summaries. 3. Quality. 4. Nonclinical study reports. 5. Clinical study reports.
- CMC, nonclinical PhC/TX, human PhK/BA/BE, Microbio(anti-inf. drugs) & Clin.Trials Summaries
- List of applicable standards and certification
- Claimed exclusivity or Licensing agreements if so
- Authorized Representative under POA see GP-PhR-AR-SR card
- Patent or Regulatory Intelligence Report see GP-PhR-RI-SR card
- Identifying Simplified NDA (e.g. US 505) see GP-PhR-GAP-SR card
- Compliance with country-specific regulations
- QMS/QA/PV. Addit. information could be required
Nice-to-have
- cGCP
- cGLP
- cISO 9001
- cISO 27001
- cISO 14001
- cISO 45001
Typical Gaps and Deficiencies: Insufficient data, incomplete documentation, non-compliance with regulatory guidelines
Implementation Period: After Approval
Deliverables: MA, methods of state controls, NRA post-marketing guidelines and requirements
PHASE | TASK | TASK | START | DURATION | Fee | KPI | ||
NUMBER | TITLE | OWNER | W/M/Q/Y | in weeks | 3rd Party | Service | State | |
0 | In-house Pre-Submission Activity | |||||||
0.1 | NDA signing or validation | Executor | week 1 | 1 | ||||
0.2 | Contract Closing | MAH | week 1 | 1 | ||||
0.3 | POA issuance and shipping | MAH | week 1 | 1 | ||||
0.4 | Invoice is sent to MAH and paid | Executor | week 1 | 1 | ||||
0.5 | Legal Document processing | Executor | week 2 | 1 | ||||
0.6 | Legal Document Translations, Notary, and Apostilles | 3rd party | week 2 | 2 | ||||
0.7 | SOW is approved by MAH | Executor | week 4 | 1 | SOW | |||
I | Submission | |||||||
I.1 | Providing documents and registration file | MAH | week 5 | 1 | ||||
I.2 | Ensure alignment with local regulatory guidelines | Executor | week 6 | 2 | ||||
I.3 | Translations and document processing | 3rd party | week 8 | 2 | ||||
I.4 | Filling out the application form | Executor | week 10 | 1 | ||||
I.5 | Approval of the application form | MAH | week 10 | 1 | ||||
I.6 | Submission of the New Drug Application and Reg. File | Executor | week 11 | 1 | Application | |||
I.7 | NRA payment | MAH | week 11 | 1 | Confirmation | |||
II | NRA Evaluation | |||||||
II.1 | Application review | NRA | week 12 | 2 | ||||
II.2 | Registration file review | NRA | week 13 | 4 | ||||
II.3 | Determining of Specific lab testing requirements | NRA | week 17 | 1 | ||||
II.4 | State-approved lab contracting | Executor | week 18 | 2 | ||||
II.5 | Samples and Ref. Standards permit obtaining | Executor | week 20 | 1 | ||||
II.6 | Samples and Ref. Standards shipping | MAH | week 21 | 2 | ||||
II.7 | Samples and Ref. Standards custom clearance | Executor | week 23 | 1 | ||||
II.8 | Optional clinical evaluation (in some countries) | Executor | week 24 | 8 | ||||
II.9 | Verification of medication guidelines and drug labeling | NRA | week 32 | 2 | ||||
II.10 | Verification of DHCP Letter and Communication Plan | NRA | week 32 | 2 | ||||
II.11 | Approval or Query | NRA | week 33 | 1 | Approval or Q&A | |||
III | Q&A | |||||||
III.1 | Analysis and addressing Qs to MAH | Executor | Mnth 8 | 1 | ||||
III.2 | Answering with relevant documents | MAH | Mnth 8 | 1 | ||||
III.3 | Official Response Evaluation | NRA | Mnth 8 | 1 | ||||
III.4 | Approval or Query | NRA | Mnth 8 | 1 | Approval or Q&A | |||
IV | Approval | |||||||
IV.1 | Market Authorization Approval | NRA | Mnth 9 | 1 | ||||
IV.2 | Reporting to MAH, compliance check | Executor | Mnth 10 | 1 | Approval | |||
IV.3 | Listing in the state register | Executor | Mnth 10 | 1 | Listing | |||
F | Final Phase In-house Post-Authorization Activity | |||||||
F.1 | Service Acceptance Certificate signing | MAH | Mnth 10 | 1 | ||||
F.2 | Final Invoice | Executor | Mnth 10 | 1 | ||||
F.3 | Final Payment | MAH | Mnth 10 | 1 | ||||
F.4 | Contract Termination | Executor | Mnth 10 | 1 | ||||
F.5 | Archiving and limiting access | Executor | Mnth 10 | 1 | Archiving |
Feel free to submit a Request for Proposal (RFP) for a specific country or territory to info@patternofusa.com